Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Cellectis

NASDAQ CLLS
$3.06 0.02 0.65%
Today share price
France
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 17 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

219.56M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
124.96M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
2.22
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
71.75M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-0.65 %

Upcoming events Cellectis

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Cellectis

Stock analysis Cellectis

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
-1.93 28.42
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
2.59 4.33
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
-1.46 9.95
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
1.11 0.65
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
-134.43 7.67

Price change Cellectis per year

11.83$ 34.71$
Min Max

Summary analysis Cellectis

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Cellectis

Revenue and net income Cellectis

All parameters

Stock news Cellectis

All news
1 November 2023 в 14:35

Cellectis’ stock is the biggest gainer and most active premarket after equity investment, collaboration pact with AstraZeneca

1 November 2023 в 14:25

Cellectis Shares Soar Premarket on AstraZeneca Deal

1 November 2023 в 14:25

Cellectis Shares Soar Premarket on AstraZeneca Deal

1 November 2023 в 10:50

AstraZeneca to Invest $245 Million in Deal With Cellectis

1 November 2023 в 10:50

AstraZeneca to Invest $245 Million in Deal With Cellectis

23 January 2023 в 21:15

Cellectis Up 11% After Cytovia Note Revision

23 January 2023 в 21:15

Cellectis Up 11% After Cytovia Note Revision

30 December 2022 в 01:20

Mayflower Bioventures Launches First Spinout in Strategic Collaboration with Cellectis

30 December 2022 в 01:20

Mayflower Bioventures Launches First Spinout in Strategic Collaboration with Cellectis

28 April 2022 в 00:45

ADRs End Lower, BRF SA, Cellectis SA Trade Actively

28 April 2022 в 00:45

ADRs End Lower, BRF SA, Cellectis SA Trade Actively

About company Cellectis

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. The company was founded in 1999 and is headquartered in Paris, France.
Address:
8, rue de la Croix Jarry, Paris, France, 75013
Company name: Cellectis
Issuer ticker: CLLS
ISIN: US15117K1034
Country: France
Exchange: NASDAQ
Currency: $
IPO date: 2007-02-07
Sector: Healthcare
Industry: Biotechnology
Site: https://www.cellectis.com

On which stock exchange are Cellectis (CLLS) stocks traded?

Cellectis (CLLS) stocks are traded on NASDAQ.

What is the ticker of Cellectis stocks (CLLS)?

The stock ticker of Cellectis’s stocks or in other words, the code is CLLS. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Cellectis (CLLS) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Cellectis (CLLS) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are Cellectis (CLLS) stocks traded?

Cellectis (CLLS) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Cellectis (CLLS) stocks today?

The current price of Cellectis stocks on 16.05.2024 is 3.06 dollars. per share.

What is the dynamics of Cellectis (CLLS) stocks from the beginning of the year?

Cellectis (CLLS) quotes have increased by -0.33% from the beginning of the year up to 3.06 dollars. per 1 stocks.

How much did Cellectis (CLLS) stocks increase in мае 2024?

This month Cellectis (CLLS) quotes have increased by 20.66% to 3.06 dollars. per share.

How much are Cellectis (CLLS) stocks worth?

Today, on October, 16.05.2024 Cellectis’s (CLLS) stocks cost 3.06 dollars..

What is the market capitalization of Cellectis (CLLS)?

Capitalization is the market value of Cellectis (CLLS) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 16.05.2024, the market capitalization of Cellectis (CLLS) is estimated at about 219558675 dollars.